Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 987 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The shares were sold at an average price of $27.20, for a total value of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The shares were sold at an average price of $26.19, for a total transaction of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The stock was sold at an average price of $23.15, for a total transaction of $20,696.10.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $27.69 on Thursday. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $28.88. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.92. The company’s 50-day moving average is $25.91 and its two-hundred day moving average is $24.27. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently modified their holdings of BLFS. Bank of New York Mellon Corp raised its holdings in BioLife Solutions by 3.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 275,570 shares of the medical equipment provider’s stock valued at $5,905,000 after acquiring an additional 8,216 shares during the last quarter. Rhumbline Advisers lifted its position in BioLife Solutions by 4.7% during the second quarter. Rhumbline Advisers now owns 87,473 shares of the medical equipment provider’s stock worth $1,875,000 after buying an additional 3,912 shares during the period. Arizona State Retirement System purchased a new position in BioLife Solutions during the second quarter worth about $217,000. Los Angeles Capital Management LLC acquired a new stake in BioLife Solutions in the 2nd quarter worth about $430,000. Finally, Texas Permanent School Fund Corp grew its holdings in BioLife Solutions by 8.7% in the 2nd quarter. Texas Permanent School Fund Corp now owns 33,859 shares of the medical equipment provider’s stock valued at $726,000 after buying an additional 2,714 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Craig Hallum lifted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. TD Cowen boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright cut their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.